HC Wainwright Comments on Zynex’s Q1 Earnings (NASDAQ:ZYXI)

Zynex, Inc. (NASDAQ:ZYXI) – Analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Zynex in a research report issued on Wednesday, March 12th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.20) per share for the quarter, down from their previous estimate of $0.07. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Zynex’s current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Zynex’s Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.40) EPS.

Zynex (NASDAQ:ZYXI) last released its earnings results on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business had revenue of $45.98 million for the quarter, compared to analysts’ expectations of $53.65 million. During the same quarter last year, the company posted $0.04 earnings per share.

A number of other equities analysts also recently commented on ZYXI. LADENBURG THALM/SH SH downgraded Zynex from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Royal Bank of Canada downgraded Zynex from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $11.00 to $5.50 in a report on Wednesday, March 12th.

Zynex Stock Performance

NASDAQ ZYXI opened at $2.64 on Monday. The business’s 50-day moving average price is $7.21 and its 200 day moving average price is $7.84. Zynex has a twelve month low of $2.61 and a twelve month high of $13.19. The company has a market capitalization of $84.25 million, a PE ratio of 17.60 and a beta of 0.81. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Institutional Investors Weigh In On Zynex

A number of large investors have recently modified their holdings of the stock. Investment Partners Asset Management Inc. grew its stake in shares of Zynex by 10.4% in the fourth quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company’s stock valued at $104,000 after buying an additional 1,220 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Zynex by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock valued at $334,000 after buying an additional 1,318 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Zynex by 6.2% in the fourth quarter. Bank of America Corp DE now owns 24,114 shares of the company’s stock valued at $193,000 after buying an additional 1,407 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Zynex by 4.4% in the fourth quarter. American Century Companies Inc. now owns 35,696 shares of the company’s stock valued at $286,000 after buying an additional 1,516 shares in the last quarter. Finally, Connors Investor Services Inc. grew its stake in shares of Zynex by 5.7% in the fourth quarter. Connors Investor Services Inc. now owns 29,858 shares of the company’s stock valued at $239,000 after buying an additional 1,608 shares in the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Insider Transactions at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the sale, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 30,000 shares of company stock worth $227,100 in the last three months. 52.13% of the stock is currently owned by company insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.